Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: A retrospective analysis of pooled data from 2 phase III randomized clinical trials

Clinical Breast Cancer

Volumn 12, Issue 4, 2012, Pages 240-246

  Valero, Vicente ^a   Vrdoljak, Eduard ^b   Xu, Binghe ^c   Thomas, Eva ^d   Gómez, Henry ^e   Manikhas, Alexey ^f   Medina, Carlos ^g   Li, Rubi Khaw ^h   Ro, Jungsil ⁱ   Bosserman, Linda ^j   Vahdat, Linda ^k   Mukhopadhyay, Pralay ^l   Opatt, Diane ^l   Sparano, Joseph A ^m  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c CANCER HOSPITAL   (China)

^d KAISER PERMANENTE   (United States)

^e INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^f St Petersburg Oncological City Hospital   (Russian Federation)

^g Centro Medica San Roque   (Argentina)

^h ST LUKE S MEDICAL CENTER   (Philippines)

ⁱ National Cancer Center   (South Korea)

^j Wilshire Oncology   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

^m MONTEFIORE MEDICAL CENTER   (United States)

more..

Author keywords

Epothilones; Microtubules; Minimizing toxicity; Treatment tolerability

Indexed keywords

CAPECITABINE; IXABEPILONE;

ADULT; AGED; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84864756216     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.03.013     Document Type: Article

References (20)

1. D.M. Bollag, P.A. McQueney, J. Zhu Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 1995 2325 2333
2. L.B. Michaud The epothilones: how pharmacology relates to clinical utility Ann Pharmacother 43 2009 1294 1309
3. C.J. Bode, M.L. Gupta Jr, E.A. Reiff Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules Biochemistry 41 2002 3870 3874 (Pubitemid 34251025)
4. F.Y. Lee, R. Borzilleri, C.R. Fairchild BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 2001 1429 1437 (Pubitemid 32708699)
5. F.Y. Lee, R. Smykla, K. Johnston Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemother Pharmacol 63 2009 201 212
6. C. Dumontet, M.A. Jordan, F.F. Lee Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies Mol Cancer Ther 8 2009 17 25
7. J.A. Low, S.B. Wedam, J.J. Lee Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer J Clin Oncol 23 2005 2726 2734 (Pubitemid 46179462)
8. H. Roché, L. Yelle, F. Cognetti Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 2007 3415 3420 (Pubitemid 47310877)
9. E. Thomas, J. Tabernero, M. Fornier Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 2007 3399 3406 (Pubitemid 47310875)
10. N. Denduluri, J.A. Low, J.J. Lee Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 2007 3421 3427 (Pubitemid 47310878)
11. E.A. Perez, G. Lerzo, X. Pivot Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414 (Pubitemid 47310876)
12. F.Y. Lee, G. Camuso, X. Castenada Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts J Clin Oncol 24 597suppl 2006 abstract 12017 www.asco.org Accessed: April 23, 2012
13. C. Bunnell, L. Vahdat, L. Schwartzberg Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer Clin Breast Cancer 8 2008 234 241 (Pubitemid 351962144)
14. E.S. Thomas, H.L. Gomez, R.K. Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 2007 5210 5217 (Pubitemid 350232252)
15. J.A. Sparano, E. Vrdoljak, O. Rixe Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 2010 3256 3263
16. ® kit (ixabepilone) for injection: prescribing information 2010 Bristol-Myers Squibb Princeton NJ
17. R.J. Lechleider, E. Kaminskas, X. Jiang Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies Clin Cancer Res 14 2008 4378 4384
18. B.T. Hennessy, A.M. Gauthier, L.B. Michaud Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 16 2005 1289 1296 (Pubitemid 41158473)
19. D. Rossi, P. Alessandroni, V. Catalano Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer Clin Breast Cancer 7 2007 857 860
20. A.D. Seidman, C.A. Hudis, J. Albanell Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 1998 3353 3361 (Pubitemid 28481632)